Sonia Hallen is a Vice President in the EQT Life Sciences team, focused on unlisted equities. She is a Director on the Board of ViCentra, and Observer on the Boards of Evommune and NOBI. Previously, Sonia was a Strategy Consultant in the Life Sciences practice of Accenture in London, UK and a Stem Cell Scientist at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Melbourne, Australia. Sonia holds a PhD in Bioengineering & Regenerative Medicine from Imperial College London.